Logo image of ALDVI.PA

ADVICENNE (ALDVI.PA) Stock Fundamental Analysis

EPA:ALDVI - Euronext Paris - Matif - FR0013296746 - Common Stock - Currency: EUR

1.186  +0.03 (+2.24%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ALDVI. ALDVI was compared to 51 industry peers in the Pharmaceuticals industry. ALDVI may be in some trouble as it scores bad on both profitability and health. ALDVI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALDVI has reported negative net income.
In the past year ALDVI has reported a negative cash flow from operations.
ALDVI had negative earnings in each of the past 5 years.
ALDVI had a negative operating cash flow in each of the past 5 years.
ALDVI.PA Yearly Net Income VS EBIT VS OCF VS FCFALDVI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

1.2 Ratios

With a Return On Assets value of -81.11%, ALDVI is not doing good in the industry: 88.24% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -81.11%
ROE N/A
ROIC N/A
ROA(3y)-69.73%
ROA(5y)-67.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALDVI.PA Yearly ROA, ROE, ROICALDVI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALDVI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALDVI.PA Yearly Profit, Operating, Gross MarginsALDVI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

ALDVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALDVI remains at a similar level compared to 1 year ago.
The number of shares outstanding for ALDVI has been increased compared to 5 years ago.
The debt/assets ratio for ALDVI is higher compared to a year ago.
ALDVI.PA Yearly Shares OutstandingALDVI.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ALDVI.PA Yearly Total Debt VS Total AssetsALDVI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

ALDVI has an Altman-Z score of -10.34. This is a bad value and indicates that ALDVI is not financially healthy and even has some risk of bankruptcy.
ALDVI has a worse Altman-Z score (-10.34) than 82.35% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.34
ROIC/WACCN/A
WACC6.74%
ALDVI.PA Yearly LT Debt VS Equity VS FCFALDVI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

ALDVI has a Current Ratio of 0.36. This is a bad value and indicates that ALDVI is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.36, ALDVI is doing worse than 88.24% of the companies in the same industry.
ALDVI has a Quick Ratio of 0.36. This is a bad value and indicates that ALDVI is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ALDVI (0.26) is worse than 88.24% of its industry peers.
Industry RankSector Rank
Current Ratio 0.36
Quick Ratio 0.26
ALDVI.PA Yearly Current Assets VS Current LiabilitesALDVI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.13% over the past year.
The Revenue has been growing slightly by 4.75% in the past year.
Measured over the past years, ALDVI shows a quite strong growth in Revenue. The Revenue has been growing by 9.63% on average per year.
EPS 1Y (TTM)14.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.76%
Revenue 1Y (TTM)4.75%
Revenue growth 3Y-0.46%
Revenue growth 5Y9.63%
Sales Q2Q%4.94%

3.2 Future

Based on estimates for the next years, ALDVI will show a very strong growth in Earnings Per Share. The EPS will grow by 27.10% on average per year.
Based on estimates for the next years, ALDVI will show a very strong growth in Revenue. The Revenue will grow by 37.89% on average per year.
EPS Next Y26.92%
EPS Next 2Y27.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year54.05%
Revenue Next 2Y39.5%
Revenue Next 3Y37.89%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALDVI.PA Yearly Revenue VS EstimatesALDVI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M
ALDVI.PA Yearly EPS VS EstimatesALDVI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALDVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALDVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALDVI.PA Price Earnings VS Forward Price EarningsALDVI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALDVI.PA Per share dataALDVI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

ALDVI's earnings are expected to grow with 27.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.1%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALDVI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADVICENNE

EPA:ALDVI (8/8/2025, 7:00:00 PM)

1.186

+0.03 (+2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-25 2025-07-25
Earnings (Next)N/A N/A
Inst Owners23%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.86M
Analysts84.44
Price Target4.07 (243.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.19%
PT rev (3m)-0.19%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)83.87%
Revenue NY rev (3m)83.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.53
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.19
BVpS-1.22
TBVpS-1.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.73%
ROA(5y)-67.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.81%
Cap/Sales 26.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.36
Quick Ratio 0.26
Altman-Z -10.34
F-Score3
WACC6.74%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.76%
EPS Next Y26.92%
EPS Next 2Y27.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.75%
Revenue growth 3Y-0.46%
Revenue growth 5Y9.63%
Sales Q2Q%4.94%
Revenue Next Year54.05%
Revenue Next 2Y39.5%
Revenue Next 3Y37.89%
Revenue Next 5YN/A
EBIT growth 1Y-34.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.26%
OCF growth 3YN/A
OCF growth 5YN/A